Active, not recruiting Dermatitis, Atopic trials in Chile: Trial Insights

Filters: Condition: Dermatitis, Atopic Status: Active, not recruiting Country / region: Chile Clear all

5 trials match Source: ClinicalTrials.gov registrations

Trials

Showing 1 to 5 of 5. Each trial links to its page on Pharma Observatory.

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Phase 3Active, not recruitingAbbVieStarted 2024
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis NCT06407934Phase 3Active, not recruitingSanofiStarted 2024
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor NCT06241118Phase 3Active, not recruitingSanofiStarted 2024
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis NCT05769777Phase 2Active, not recruitingSanofiStarted 2023
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials NCT05492578Phase 2/3Active, not recruitingSanofiStarted 2022

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Status changeRecruiting to Active, not recruitingOctober 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Enrollment change675 to 699October 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Completion date change2030-07-31 to 2029-11-30October 18, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory